Zai Lab and Pfizer collaborate to address drug-resistant infections in China
Zai Lab and Pfizer have entered a partnership to commercialize XACDURO (sulbactam-durlobactam) in mainland China, addressing the rising threat of drug-resistant infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB). With Pfizer’s robust infrastructure and Zai Lab’s innovative drug development, this collaboration aims to expedite access to this life-saving therapy, especially for critically ill patients. The collaboration […]